skip to main content

Our Private Equity Group is considered the go-to practice for complex, bespoke and firm-defining transactions. With clients ranging from the world’s leading institutional asset managers to prominent middle-market private equity and growth equity firms, we offer comprehensive advice to general partners, limited partners, co-investors and other equity stakeholders, as well as portfolio companies, lenders and financial sponsor groups. The depth and continuity of our relationships across the industry gives us a nuanced understanding of each client’s objectives and allows us to provide seamless, efficient counsel across the investment lifecycle.

General Atlantic to Sell Stake in OneOncology to TPG and AmerisourceBergen

Paul, Weiss is advising General Atlantic and portfolio company OneOncology in the sale of OneOncology to global alternative asset management firm TPG and global pharmaceutical solutions organization AmerisourceBergen Corporation. The transaction values OneOncology, a network of leading oncology practices, at $2.1 billion.

Under the terms of the deal, TPG, AmerisourceBergen and OneOncology’s affiliated practices, physicians and management team will form a new joint venture that will acquire OneOncology from majority owner General Atlantic and other shareholders. TPG will acquire a majority interest in the company, and AmerisourceBergen and the OneOncology affiliate team will each acquire minority interests. The transaction is subject to customary closing conditions and regulatory approvals.

The Paul, Weiss team is led by corporate partners Matthew Abbott and Ellen Ching, and includes corporate partner Suhan Shim; tax partner Lindsay Parks; litigation partners Joshua Soven and Andrew Gordon and counsel Steven Herzog; intellectual property partner Charles Googe; executive compensation partner Jarrett Hoffman; real estate partner Peter Fisch; and environmental counsel William O’Brien.

© 2024 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy